May 26th, 2021 | 08:15 CEST
BioNTech, PsyBio, Bayer: The opportunities of tomorrow
Table of contents:
"[...] Since inflammation is a cause of heart failure, and heart failure in turn is one of the leading causes of death in the Western world [...]" David Elsley, CEO, Cardiol Therapeutics
BioNTech: Come to stay
BioNTech's vaccine could be a constant companion for people in the future. Viral variants are constantly emerging and the protection of existing vaccines is gradually declining. So far, BioNTech has shown good protection against viral variants, but early voices already expect that there may be a booster starting in the fall. For BioNTech, this circumstance is good news - after all, the vaccine manufacturer specializing in mRNA technology should continue to receive orders for years to come.
The discussion about the cancellation of patent protection is also likely to affect BioNTech less than initially thought. The Mainz-based Company does not want to give up patent protection but wants to accommodate poorer countries. This practice could be a compromise that promises BioNTech continued good business. On the stock market, the share is currently moving sideways. However, given the significant increase in the previous months, this is not a disaster. In addition, BioNTech can also score in other areas with its expertise in mRNA technology. The share is expensive, but the Company is good. However, the share price potential is limited.
PsyBio: Biotech newcomer continues to collect patents
What mRNA technology was a few years ago is what the active ingredient psilocybin is now. The psychoactive substance from mushrooms is soon to be launched on the market as a drug. The US biotech Company PsyBio researches psilocybin and related active ingredients in close cooperation with universities and research institutes. Thanks to this research work, the Company has succeeded in filing several patents. The Company recently added a new patent around improved methods for the production of psilocybin and by-products. PsyBio focuses on producing active ingredients synthetically using bacteria rather than from mushrooms.
In doing so, the Company is taking a similar approach to what Bayer did with aspirin many years ago. The formerly herbal active ingredient was synthesized and thus became an effective drug with consistent dose and quality. PsyBio wants to follow a similar path with its active ingredients to combat depression. While classic medications for depression still have a strong impact on patients' bodies, psychoactive substances based around psilocybin have the potential to take effect quickly. Users report formative experiences after just one use. Fears around palliative treatment, for example, could be addressed. The PsyBio share is currently suffering from the market environment. However, investors should note the value. With a market capitalization of only around EUR 20 million, things can move quickly here.
Bayer: Things are moving forward!
Bayer is currently showing that companies whose share price has hit rock bottom can be quite promising. Battered by the glyphosate scandal, the share has lost steadily in recent years. The Company is still suffering from pending litigation. But, the stock promises a lot: In addition to a dividend yield of more than 5%, the Company also shines with a high EBITDA margin. Although Bayer is rebuilding itself and has not yet tackled all problem areas, the chemical group's stock has already risen in recent months. The EUR 56 mark could prove to be resistance in the short term.
Exciting years lie ahead for the pharmaceutical and chemical sectors. Investors could see new technology less as a risk and more as an opportunity after the Corona disaster. On the one hand, this applies to digital solutions but also innovative active ingredients. There are already accelerated approval processes in the wake of the pandemic - the best example being vaccines. In the next step, biotech companies could also benefit from the realization that things can be done faster. While stocks such as BioNTech are already the talk of the town, the much more speculative PsyBio is still completely unknown. Opportunity-oriented investors can take a closer look at this stock.
Conflict of interest
Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") may in the future hold shares or other financial instruments of the mentioned companies or will bet on rising or falling on rising or falling prices and therefore a conflict of interest may arise in the future. conflict of interest may arise in the future. The Relevant Persons reserve the shares or other financial instruments of the company at any time (hereinafter referred to as the company at any time (hereinafter referred to as a "Transaction"). "Transaction"). Transactions may under certain circumstances influence the respective price of the shares or other financial instruments of the of the Company.
Furthermore, Apaton Finance GmbH reserves the right to enter into future relationships with the company or with third parties in relation to reports on the company. with regard to reports on the company, which are published within the scope of the Apaton Finance GmbH as well as in the social media, on partner sites or in e-mails, on partner sites or in e-mails. The above references to existing conflicts of interest apply apply to all types and forms of publication used by Apaton Finance GmbH uses for publications on companies.
Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and etc. on news.financial. These contents serve information for readers and does not constitute a call to action or recommendations, neither explicitly nor implicitly. implicitly, they are to be understood as an assurance of possible price be understood. The contents do not replace individual professional investment advice and do not constitute an offer to sell the share(s) offer to sell the share(s) or other financial instrument(s) in question, nor is it an nor an invitation to buy or sell such.
The content is expressly not a financial analysis, but rather financial analysis, but rather journalistic or advertising texts. Readers or users who make investment decisions or carry out transactions on the basis decisions or transactions on the basis of the information provided here act completely at their own risk. There is no contractual relationship between between Apaton Finance GmbH and its readers or the users of its offers. users of its offers, as our information only refers to the company and not to the company, but not to the investment decision of the reader or user. or user.